It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Reactive astrocytes play a pivotal role in the pathogenesis of neurological diseases; however, their functional phenotype and the downstream molecules by which they modify disease pathogenesis remain unclear. Here, we genetically increase P2Y1 receptor (P2Y1R) expression, which is upregulated in reactive astrocytes in several neurological diseases, in astrocytes of male mice to explore its function and the downstream molecule. This astrocyte-specific P2Y1R overexpression causes neuronal hyperexcitability by increasing both astrocytic and neuronal Ca2+ signals. We identify insulin-like growth factor-binding protein 2 (IGFBP2) as a downstream molecule of P2Y1R in astrocytes; IGFBP2 acts as an excitatory signal to cause neuronal excitation. In neurological disease models of epilepsy and stroke, reactive astrocytes upregulate P2Y1R and increase IGFBP2. The present findings identify a mechanism underlying astrocyte-driven neuronal hyperexcitability, which is likely to be shared by several neurological disorders, providing insights that might be relevant for intervention in diverse neurological disorders.
Reactive astrocytes display aberrant Ca2+ signals. Here, the authors show a link between P2Y1 receptor, a major regulator of the aberrant Ca2+ signals, and IGFBP2 that may lead to neuronal hyperexcitability in neurological disorders.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 University of Yamanashi, Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, Yamanashi, Japan (GRID:grid.267500.6) (ISNI:0000 0001 0291 3581); University of Yamanashi, Yamanashi GLIA center, Yamanashi, Japan (GRID:grid.267500.6) (ISNI:0000 0001 0291 3581)
2 University of Yamanashi, Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, Yamanashi, Japan (GRID:grid.267500.6) (ISNI:0000 0001 0291 3581)
3 University of Yamanashi, Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, Yamanashi, Japan (GRID:grid.267500.6) (ISNI:0000 0001 0291 3581); University of Yamanashi, Yamanashi GLIA center, Yamanashi, Japan (GRID:grid.267500.6) (ISNI:0000 0001 0291 3581); University of Yamanashi, Department of Pediatrics, Faculty of Medicine, Yamanashi, Japan (GRID:grid.267500.6) (ISNI:0000 0001 0291 3581)
4 Kyushu University, Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Fukuoka, Japan (GRID:grid.177174.3) (ISNI:0000 0001 2242 4849)
5 Kyushu University, Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Fukuoka, Japan (GRID:grid.177174.3) (ISNI:0000 0001 2242 4849); Hyogo College of Medicine, Department of Neurophysiology, Hyogo, Japan (GRID:grid.272264.7) (ISNI:0000 0000 9142 153X)
6 University of Yamanashi, Department of Neurosurgery, Interdisciplinary Graduate School of Medicine, Yamanashi, Japan (GRID:grid.267500.6) (ISNI:0000 0001 0291 3581)
7 Keio University School of Medicine, Division of Brain Sciences, Institute for Advanced Medical Research, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959)
8 The University of Tokyo, Department of Neurochemistry, Graduate School of Medicine, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2169 1048)
9 Kyushu University, Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Fukuoka, Japan (GRID:grid.177174.3) (ISNI:0000 0001 2242 4849); Kyushu University, Department of Life Innovation, Graduate School of Pharmaceutical Sciences, Fukuoka, Japan (GRID:grid.177174.3) (ISNI:0000 0001 2242 4849)